Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 12, Issue 3, 1984, Pages 263-287

  Hinderling, Peter H ^a   Schmidlin, Olga ^a   Seydel, Jochen K ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

beta adrenoceptor blocking agents; lipophilicity; octanol water partition coefficient; pharmacokinetics; structure

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BUFURALOL; METOPROLOL; NADOLOL; OXPRENOLOL; PENBUTOLOL; PINDOLOL; PRACTOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; TOLAMOLOL;

AUTONOMIC NERVOUS SYSTEM; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; LIPOPHILICITY; NORMAL HUMAN; PARTITION COEFFICIENT; PHARMACOKINETICS; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-ANTAGONISTS; HUMAN; HYDROGEN-ION CONCENTRATION; KIDNEY; KINETICS; METABOLIC CLEARANCE RATE; REGRESSION ANALYSIS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0021175109     PISSN: 0090466X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/BF01061721     Document Type: Article

References (71)

1. Protein binding of antimicrobials, clinical pharmacokinetics and therapeutic implications
2. Plasma and tissue protein binding of drugs in pharmacokinetics
3. Quantitative Struktur-Pharmacokinetik-Beziehungen am Beispiel von Sulfonamidobenzolen und Sulfanilamidopyridinen
4. Kinetics and biotransformation of adrenergic inhibitors
5. Inhibition of drug metabolism by beta-adrenoceptor antagonists
6. Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists?
7. Beta-adrenoceptor blockers and the blood-brain barrier
8. Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high performance liquid chromatography and their correlation
9. Lipophilicity and brain disposition of clonidine and structurally related imidazolidines
10. Bestimmung der Testzeit in der “Reversed-Phase” Hochdruckflüssigkeits-Chromatographie
11. Passage of organic bases into human red cells
12. The binding of sulfonamide drugs by plasma proteins. A factor in determining the distribution of drugs in the body
13. Apparent volumes of distribution and drug binding to plasma proteins and tissues
14. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time
15. Glornerular filtration rate and creatinine clearance
16. Physico-chemical and analytical studies of penbutolol
17. The buccal absorption of some beta-adrenoceptor blocking drugs
18. Comparison of plasma and saliva levels of metoprolol and oxprenolol
19. Pharmacokinetic studies on the selective beta,-receptor antagonist metoprolol in man
20. The binding characteristics of some adrenergic betareceptor antagonists to human serum proteins
21. Separation and spectrofluorometric assay of the betaadrenergic blocker sotalol from blood and urine
22. Measurement of hydrophobicity, surface activity, local anesthesia and myocardial conduction velocity as quantitative parameters of the non-specific membrane affinity of nine beta-adrenergic blocking agents
23. The pharmacokinetic characteristics of beta-receptor antagonists in man-similarities and differences of clinical relevance
24. Blood plasma binding of acebutolol and diacetolol in man
25. Binding of adrenergic beta-receptor-antagonists to human serum albumin
26. An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents
27. Pharmacokinetic and pharmacological studies with tolamolol in man
28. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha1-glycoprotein and to human serum
29. Acebutolol disposition after intravenous administration
30. Effect of pH on human plasma protein binding of a series of beta-adrenoceptor antagonists
31. Metabolic studies in patients with nadolol: oral and intravenous administration
32. Human pharmacokinetics of sotalol
33. Uptake of propranolol by washed human red cells
34. Effect of pentobarbital on the disposition of alprenolol
35. Practolol metabolism II. Metabolism in human subjects
36. Importance of first pass elimination for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol
37. The disposition of timolol in man
38. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function
39. Pindolol availability in hypertensive patients with normal and impaired renal function
40. Kinetics and absolute bioavailability of atenolol
41. Influence of renal failure on the hepatic clearance of bufuralol in man
42. The predictable relationship between plasma levels and dose during chronic propranolol therapy
43. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol
44. Factors influencing the absorption of oxprenolol, a pharmacokinetic study
45. Timolol kinetics in chronic renal insufficiency
46. Lack of biological interaction of alprenolol and salicylate in man
47. Simultaneous tubular excretion and reabsorption of pindolol in man
48. Pharmacokinetics of propranolol in normal healthy volunteers
49. Plasma timolol levels after oral and intravenous administration
50. Pharmacokinetics of oxprenolol in normal subjects
51. Comparative pharmacokinetics of benzodiazepines in dog and man